Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Japan To Lower Price Of Eight Drugs From Takeda, Novartis, BMS And Chugai By 12-18 Percent

This article was originally published in PharmAsia News

Executive Summary

As part of an ongoing re-pricing policy for drugs that have seen expanded market share, Japan's Ministry of Health, Labor and Welfare has decided to lower the price on eight drugs effective April 1

You may also be interested in...



Japan Sets New Reimbursement Prices For NHI-qualified Drugs; Cuts Average 5.75 Percent

TOKYO - Japan's Ministry of Health, Labor and Welfare March 5 posted new reimbursement prices of National Health Insurance-qualified drugs, the first such change in two years. The new prices are effective April 1

Japan Sets New Reimbursement Prices For NHI-qualified Drugs; Cuts Average 5.75 Percent

TOKYO - Japan's Ministry of Health, Labor and Welfare March 5 posted new reimbursement prices of National Health Insurance-qualified drugs, the first such change in two years. The new prices are effective April 1

Chugai Sets Record Results In 2009, Lowers Forecasts For 2010

Roche Japanese unit Chugai Pharmaceutical had its best year ever in 2009, posting record revenue and profits thanks largely to Tamiflu (oseltamivir), which saw Japan sales soar nine-fold to ¥76.2 billion ($852.75 million) in response to the Japanese government and local authorities stockpiling flu drugs

Related Content

UsernamePublicRestriction

Register

SC074469

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel